Full text

Turn on search term navigation

© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Hypercoagulable state is linked to cancer progression; however, the precise role of the coagulation cascade is poorly described. Herein, we examined the contribution of a hypercoagulative state through the administration of intravenous Coagulation Factor Xa (FXa), on the growth of solid human tumors and the experimental metastasis of the B16F10 melanoma in mouse models. FXa increased solid tumor volume and lung, liver, kidney and lymph node metastasis of tail-vein injected B16F10 cells. Concentrating on the metastasis model, upon coadministration of the anticoagulant Dalteparin, lung metastasis was significantly reduced, and no metastasis was observed in other organs. FXa did not directly alter proliferation, migration or invasion of cancer cells in vitro. Alternatively, FXa upon endothelial cells promoted cytoskeleton contraction, disrupted membrane VE-Cadherin pattern, heightened endothelial-hyperpermeability, increased inflammatory adhesion molecules and enhanced B16F10 adhesion under flow conditions. Microarray analysis of endothelial cells treated with FXa demonstrated elevated expression of inflammatory transcripts. Accordingly, FXa treatment increased immune cell infiltration in mouse lungs, an effect reduced by dalteparin. Taken together, our results suggest that FXa increases B16F10 metastasis via endothelial cell activation and enhanced cancer cell-endothelium adhesion advocating that the coagulation system is not merely a bystander in the process of cancer metastasis.

Details

Title
Coagulation Factor Xa Promotes Solid Tumor Growth, Experimental Metastasis and Endothelial Cell Activation
Author
Arce, Maximiliano 1 ; Pinto, Mauricio P 2   VIAFID ORCID Logo  ; Galleguillos, Macarena 3 ; Muñoz, Catalina 3 ; Lange, Soledad 3 ; Ramirez, Carolina 3 ; Erices, Rafaela 4   VIAFID ORCID Logo  ; Gonzalez, Pamela 3 ; Velasquez, Ethel 5   VIAFID ORCID Logo  ; Tempio, Fabián 6 ; Lopez, Mercedes N 7 ; Salazar-Onfray, Flavio 7 ; Cautivo, Kelly 3   VIAFID ORCID Logo  ; Kalergis, Alexis M 8 ; Cruz, Sebastián 9 ; Lladser, Álvaro 10 ; Lobos-González, Lorena 11 ; Valenzuela, Guillermo 2 ; Olivares, Nixa 2   VIAFID ORCID Logo  ; Sáez, Claudia 2 ; Koning, Tania 12 ; Sánchez, Fabiola A 12 ; Fuenzalida, Patricia 3 ; Godoy, Alejandro 13 ; Pamela Contreras Orellana 14 ; Leyton, Lisette 14   VIAFID ORCID Logo  ; Lugano, Roberta 15 ; Dimberg, Anna 15 ; Quest, Andrew FG 14   VIAFID ORCID Logo  ; Owen, Gareth I 16   VIAFID ORCID Logo 

 Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile 
 Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile 
 Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile 
 Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Vicerrectoría de Investigación, Universidad Mayor, Santiago 7510041, Chile 
 Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Comisión Chilena de Energía Nuclear (CCHEN), Santiago, Chile 
 Institute of Biomedical Sciences, Faculty of Medicine, University de Chile, Santiago 8380453, Chile 
 Institute of Biomedical Sciences, Faculty of Medicine, University de Chile, Santiago 8380453, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago 8331150, Chile 
 Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago 8331150, Chile; Biomedical Research Consortium of Chile, Santiago 8331010, Chile 
 Laboratory of Immunoncology, Fundación Ciencia & Vida, Santiago, Chile 
10  Millennium Institute on Immunology and Immunotherapy, Santiago 8331150, Chile; Laboratory of Immunoncology, Fundación Ciencia & Vida, Santiago, Chile 
11  Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile; Laboratory of Immunoncology, Fundación Ciencia & Vida, Santiago, Chile; Regenerative Medicine Center, Faculty of Medicine, Clinica Alemana-Universidad Del Desarrollo, Santiago 7650568, Chile 
12  Immunology Institute, Faculty of Medicine, Universidad Austral de Chile, Valdivia 5110566, Chile 
13  Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14203, USA 
14  Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile; Laboratory of Cellular Communication, ICBM, Faculty of Medicine, Universidad de Chile, Santiago 8380453, Chile 
15  Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden 
16  Faculty of Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Advanced Center for Chronic Diseases (ACCDiS), Santiago, Chile; Faculty of Medicine, Pontificia Universidad Católica de Chile, Santiago 8331150, Chile; Millennium Institute on Immunology and Immunotherapy, Santiago 8331150, Chile 
First page
1103
Publication year
2019
Publication date
2019
Publisher
MDPI AG
e-ISSN
20726694
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2547526473
Copyright
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.